David’s current positions include Professor of Kidney Medicine at University College London, UK and Honorary Consultant Nephrologist at the Royal Free NHS Foundation Trust. He is a Clinician Scientist with an interest in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the design, roll out and monitoring of several large-scale clinical trials. He was a member of the steering committee of the Study of Heart and Renal Protection (SHARP) and the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE). He currently sits on the steering committee of Canaglifozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), acting as UK principle investigator for this study. He is Clinical Lead for Division 2 of the North Thames Clinical Research Network and heads a team of 8 Clinical Trials Nurses/Practitioners at the Centre for Nephrology, Royal Free Hospital in London. He has been involved in Clinical Practice Guideline Development for several organisations, most recently for Kidney Disease, Improving Global Outcomes (KDIGO), of which he is currently co-chair. He is Past President of the UK Renal Association and Chair of the UK Renal Registry. Other responsibilities include Associate Editor of Nephrology, Dialysis Transplantation and member of the Editorial Board of the Journal of the American Society of Nephrology.
